Repaglinide

Drug Profile

Repaglinide

Alternative Names: AGEE 623; AGEE 623 ZW; GlucoNorm; NN 623; NovoNorm; Prandin; SMP 508; Surepost

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Novo Nordisk; Sumitomo Dainippon Pharma
  • Class Antihyperglycaemics; Carbamates; Piperidines; Small molecules
  • Mechanism of Action Insulinotropin agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 18 Nov 2014 Launched for Type-2 diabetes mellitus (Combination therapy) in Japan (PO)
  • 18 Nov 2014 Sumitomo Dainippon Pharma receives approval in Japan for partial change of the approved indications to include the use of repaglinide in combination with any oral hypoglycaemic agents, except with sulfonylurea and insulin formulations
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top